Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Confidence intervals

Barry K Moser1

  • 1CALGB Statistical Center, Duke University Medical Center, Durham, NC, USA.

Clinical Advances in Hematology & Oncology : H&O
|February 19, 2008
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sample Size Requirements for Accurate Estimation of Squared Semi-Partial Correlation Coefficients.

Multivariate behavioral research·2016
Same author

Ductal metaplasia in oesophageal submucosal glands is associated with inflammation and oesophageal adenocarcinoma.

Histopathology·2015
Same author

Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

Leukemia & lymphoma·2013
Same author

Hemorrhagic complications of thoracentesis and small-bore chest tube placement in patients taking clopidogrel.

Annals of the American Thoracic Society·2013
Same author

Post-transplantation B cell function in different molecular types of SCID.

Journal of clinical immunology·2012
Same author

Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Blood·2012
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles